Negotiation of meaning in lingua-franca interaction

Sensitivity analysis for the number of iterations and acceptance percentage using Normal distribution with mean = 50 and SD = 17. The plots in the top row display AREs for standard deviation estimate and mean estimate under S1. The plots in the middle row display AREs for standard deviation estimate and mean estimate under S2. The plots in the bottom row display AREs for standard deviation estimate and mean estimate under S3. In each plot six lines and symbols are displayed for the combination of the number of iterations and acceptance percentage. (JPEG 531 kb

Additional file 2: of Simulation-based estimation of mean and standard deviation for meta-analysis via Approximate Bayesian Computation (ABC)

Sensitivity analysis for the number of iterations and prior distribution for σ using Normal distribution with mean = 50 and SD = 17. The plots in the top row display AREs for standard deviation estimate and mean estimate under S3 with three different prior distributions for σ and 20,000 iterations. The plots in the middle row display AREs for standard deviation estimate and mean estimate under S3 with three different prior distributions for σ and 50,000 iterations. The plots in the bottom row display AREs for standard deviation estimate and mean estimate under S3 with three different prior distributions for σ and 100,000 iterations. (JPEG 377 kb

MOESM2 of Obstacles to successful treatment of hepatitis C in uninsured patients from a minority population

Additional file 2: Table S1. Univariable and multivariable logistic regression for association with treatment completion

MOESM1 of Obstacles to successful treatment of hepatitis C in uninsured patients from a minority population

Additional file 1: Figure S1. Attainment of specific milestones in the HCV treatment cascade of cirrhotic and non-cirrhotic patients. A. In patients who initiated treatment (N = 216). B. In patients who completed treatment (N = 189). C. In patients who obtained a 12-week post treatment viral load (N = 177). † Completed treatment per guidelines (based on patient report)

MOESM3 of Obstacles to successful treatment of hepatitis C in uninsured patients from a minority population

Additional file 3: Table S2. Univariable and multivariable logistic regression for association with being tested for SVR

Parameter estimates and 95% profile likelihood-based confidence intervals (95% CI) (or 95% Bayesian credible intervals (BCI)) for analysis of curvature in fits of excess odds ratio model (1) with or without adjustment for dose errors using regression calibration, for various sets of doses.

<p>^aunless otherwise stated all <i>p</i>-values refer to the improvement in fit of the current row in the Table with that of the model fitted in the row immediately above.</p><p>^b<i>p</i>-value of improvement in fit compared with a model with linear-exponential dose terms.</p><p>^c<i>p</i>-value of improvement in fit compared with a model with no dose terms.</p><p>^ddeviance information criterion [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139826#pone.0139826.ref024" target="_blank">24</a>].</p><p>^eposterior distribution maximum probability estimate.</p><p>^f95% Bayesian credibility interval (BCI).</p><p>All models have underlying rates adjusted for age (treated categorically), gender and oblast.</p

Dose-response (+95 CI) for thyroid cancer in relation to deterministic [4, 21], and regression-calibration adjusted doses (arithmetic means of 1,000 individual stochastic doses) [22].

<p>The models are adjusted for age (treated categorically), gender and oblast in the baseline. Dashed red line shows odds ratio = 1. The lower panel shows the lower dose (<0.5 Gy) part of the dose response.</p

Variation of excess relative risk with age at the time of the accident (using regression calibration adjusted doses).

<p>Other details as for <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139826#pone.0139826.g001" target="_blank">Fig 1</a>.</p

Analysis of curvature in fits of EOR model (2) with or without adjustment for dose errors using regression calibration, for TD-10 doses.

<p>All models have underlying rates adjusted for age (treated categorically) and gender. Unless otherwise stated all CI are profile-likelihood based.</p>a<p>unless otherwise stated all <i>p</i>-values refer to the improvement in fit of the current row in the Table with that of the model fitted in the row immediately above.</p>b<p><i>p</i>-value of improvement in fit compared with a model with no dose terms.</p